Shedding of infectious SARS-CoV-2 by hospitalized COVID-19 patients in relation to serum antibody responses

Autor: Maria Lind Karlberg, Max Bell, Jonas Klingström, Kimia T Maleki, Mikaela Olausson, Hedvig Glans, Wanda Christ, Sandra Broddesson, Ryan Falck-Jones, Renata Varnaite, Anna Färnert, Anna Smed-Sörensen, Sara Falck-Jones, Niclas Johansson, Sara Gredmark-Russ, Andreas Bråve
Jazyk: angličtina
Rok vydání: 2021
Předmět:
0301 basic medicine
Male
viruses
Culture
Infectious and parasitic diseases
RC109-216
Antibodies
Viral
Polymerase Chain Reaction
Severity of Illness Index
Immunoglobulin G
0302 clinical medicine
Medical microbiology
Medicine
030212 general & internal medicine
Neutralizing antibody
skin and connective tissue diseases
biology
virus diseases
Middle Aged
Virus Shedding
Hospitalization
Titer
Infectious Diseases
RNA
Viral
Female
Antibody
Adult
medicine.medical_specialty
Virus
Antibodies
COVID-19 Serological Testing
03 medical and health sciences
Microneutralization Assay
Humans
Viral shedding
Pandemics
Aged
business.industry
SARS-CoV-2
Research
fungi
Sputum
COVID-19
Antibodies
Neutralizing
respiratory tract diseases
030104 developmental biology
Cross-Sectional Studies
Immunology
biology.protein
business
Zdroj: BMC Infectious Diseases
BMC Infectious Diseases, Vol 21, Iss 1, Pp 1-9 (2021)
ISSN: 1471-2334
Popis: Background Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is a global pandemic. The understanding of the transmission and the duration of viral shedding in SARS-CoV-2 infection is still limited. Objectives To assess the timeframe and potential risk of SARS-CoV-2 transmission from hospitalized COVID-19 patients in relation to antibody response. Method We performed a cross-sectional study of 36 COVID-19 patients hospitalized at Karolinska University Hospital. Patients with more than 8 days of symptom duration were sampled from airways, for PCR analysis of SARS-CoV-2 RNA and in vitro culture of replicating virus. Serum SARS-CoV-2-specific immunoglobulin G (IgG) and neutralizing antibodies titers were assessed by immunofluorescence assay (IFA) and microneutralization assay. Results SARS-CoV-2 RNA was detected in airway samples in 23 patients (symptom duration median 15 days, range 9–53 days), whereas 13 patients were SARS-CoV-2 RNA negative (symptom duration median 21 days, range 10–37 days). Replicating virus was detected in samples from 4 patients at 9–16 days. All but two patients had detectable levels of SARS-CoV-2-specific IgG in serum, and SARS-CoV-2 neutralizing antibodies were detected in 33 out of 36 patients. Total SARS-CoV-2-specific IgG titers and neutralizing antibody titers were positively correlated. High levels of both total IgG and neutralizing antibody titers were observed in patients sampled later after symptom onset and in patients where replicating virus could not be detected. Conclusions Our data suggest that the presence of SARS-Cov-2 specific antibodies in serum may indicate a lower risk of shedding infectious SARS-CoV-2 by hospitalized COVID-19 patients.
Databáze: OpenAIRE
Externí odkaz: